


PATENT



ATTORNEY DOCKET NO. CSHL.005.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Malinow *et al*

Serial No.: 09/353,126

Filed: July 14, 1999

For: **DIAGNOSTIC METHODS FOR DRUG
SCREENING FOR ALZHEIMER'S
DISEASE**

)
) Examiner: S. L. Turner

)
) Art Unit: 1647

) **INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is:

- ☒ [X] An Information Disclosure Statement.
- ☒ [X] A PTO-1449.
- ☐ [] Copies of references listed on the PTO-1449 form.
 - ☐ [] English translation of foreign language references.
 - ☐ [] Copy of foreign examination report.
 - ☐ [] English translation of foreign examination report.
- ☒ [X] Return postcard (postage prepaid).

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on February 12, 2001

Signed

Printed

Jeffrey M. Libby

1. ☐ This Information Disclosure Statement is filed before the later of:
- ☐ three months from the filing date of this national application;
 - ☐ three months from the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or
 - ☐ the mailing date of a first office action on the merits.
- ☐ In accordance with 37 C.F.R. § 1.97(b), no fee is required.
2. ☒ This Information Disclosure Statement is filed after the events noted in paragraph 2, but before either:
- (1) a final action under 37 C.F.R. § 1.113; or
 - (2) a Notice of Allowance under 37 C.F.R. § 1.311.
- ☒ In accordance with 37 C.F.R. § 1.97(c) also enclosed is:
- ☒ a fee under 37 C.F.R. § 1.17(p) in the amount of \$210; or
 - ☐ a certification as stated below.
3. ☐ This Information Disclosure statement is filed before the payment of the issue fee, but after either:
- (1) a final action under 37 C.F.R. § 1.113; or
 - (2) a Notice of Allowance under 37 C.F.R. § 1.311.
- ☐ In accordance with 37 C.F.R. § 1.97(d) also enclosed is:
- (1) A certification, as stated below;
 - (2) A Petition requesting consideration of the Information Disclosure Statement; and
 - (3) The petition fee set forth in 37 C.F.R. § 1.17(i)(1) in the amount of \$180.

Certification

The undersigned also states:

- ☐ Each item of information contained in the Information Disclosure Statement cited herein was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.


The fees indicated above are:

TOTAL FEES: \$ 180

- ☒ For fees, see Transmittal Letter
- ☐ A check including the amount of the above-indicated TOTAL FEES is attached.
- ☐ Please charge Deposit Account No. 18-0020 in the amount of: \$ _____.
- ☐ A check in the amount of \$ _____ is attached.
- ☐ No fee is required.
- ☒ The Commissioner is hereby authorized to charge any underpayment of the following fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 18-0020.
- ☒ Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 C.F.R. § 1.17.
- ☒ A duplicate copy of this sheet is attached for accounting purposes.

Respectfully submitted,

Dated: February 12, 2001



Barbara Rae-Venter, Ph.D.
Reg. No. 32,750

Rae-Venter Law Group, P.C.
P.O. Box 60039
Palo Alto, CA 94306-0039
Telephone (650) 328-4400
Facsimile (650) 328-4477

BRV/mwy

PATENT



ATTORNEY DOCKET NO. CSHL.005.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Malinow *et al*

Serial No.: 09/353,126

Filed: July 14, 1999

For: DIAGNOSTIC METHODS FOR DRUG
SCREENING FOR ALZHEIMER'S
DISEASE

) Examiner: S. L. Turner

) Art Unit: 1647

) INFORMATION DISCLOSURE
) STATEMENT

#4
S. J.
2/23/01

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is hereby submitted in accordance with 37 CFR 1.98 and pursuant to Applicant's continuing duty under 37 CFR 1.56 to bring any information which may be material to patentability of this application to the Examiner's attention.

References C8-17 have been submitted by the Applicants in priority Application No. 09/193,221. Each of these references have been cited by or submitted to the Office in a properly identified prior application; therefore, under 37 C.F.R. §1.98(d) copies of these references are not required.

CERTIFICATE OF FIRST CLASS MAILING

02/20/2001 RHARIS1 00000054 09353126

02 FC:126

180.00 OP

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on February 12, 2001

Signed

Printed


Jeffrey M. Libby
Jeffrey M. Libby

Applicant makes no representation that a complete search has been conducted by the Applicant, or that there is not possibly more relevant art. Applicant also makes no representation that the information submitted herewith is in fact material.

The subject application is believed patentable over any of the above references.

Respectfully submitted,

Dated: February 12, 2001


Barbara Rae-Venter, Ph.D.
Reg. No. 32,750

RAE-VENTER LAW GROUP, P.C.
P.O. Box 60039
Palo Alto, CA 94306-0039
Telephone (650) 328-4400
Facsimile (650) 328-4477

BRV/JML

PATENT

COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DOCKET NO. CSHL005.01US

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 1 of 2

In re application of: Malinow *et al.*

Art Unit: 164~~7~~

Examiner: S. L. Turner

Serial No.: 09/353,126

Filed: July 14, 1999

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	Filing Date
			None			

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Filing Date
			None			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials
----------------	------------------------

C8	Bliss <i>et al.</i> (1993) <u>Nature</u> 361:31-39.
C9	Borchelt <i>et al.</i> (1996) <u>Neuron</u> 17: 1005 - 1013.
C10	Evans, <i>et al.</i> (1996) <u>Neuropharmacology</u> 35: 347-357.
C11	Fastbom <i>et al.</i> (1998) <u>Alzheimer Dis Assoc. Disord.</u> 12: 14-17.
C12	Guo <i>et al.</i> (1996) <u>Neuroreport</u> . 8: 379-383.


Examiner:

No information provided

Date Considered:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PATENT



DOCKET NO. CSHL.005.01US

COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 2 of 2

In re application of: Malinow *et al.*

]

Art Unit: 1645

]

Examiner: S. L. Turner

]

Serial No.: 09/353,126

]

Filed: July 14, 1999

C13

Muir *et al.* (1996) J. Cereb. Blood Flow Metab. (16): 1211-1218.

C14

Ohkuma *et al.* (1994) Jpn. J. Pharmacol 64:125-128.

C15

Shen, *et al.* (1997) Cell 89: 629-639.

C16

Wigstrom *et al.* (1986) J. Physiol. (Paris) 81: 228-236.

C17

Wong *et al.* (1997) Nature 387: 288-292.

Examiner:

Date Considered:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.